Genomics plc raises £25 million in Series B round to advance its use of human genetics and data science in drug discovery

Investors include Vertex, IP Group, Woodford Investment Management, Invesco Perpetual, Oxford Sciences Innovation, Lansdowne Partners and Tanarra. Proceeds will allow Genomics to expand and enhance its leading position in using sophisticated analyses of human genetic and health outcome data to transform drug discovery.

Genomics plc, the data science company specialising in the use of human genetic information to improve drug development, today announced that it has successfully closed an oversubscribed £25 million Series B financing round led by Vertex Pharmaceuticals Incorporated. Other participating investors are IP Group plc, Woodford Investment Management Ltd, Invesco Perpetual, Oxford Sciences Innovation (OSI), Lansdowne Partners and Tanarra (1).

Additionally, Genomics plc today announced a collaboration with Vertex to further advance Vertex’s efforts to develop transformative medicines for people with serious diseases.

Genomics plc will use the proceeds of this fundraising to enable further expansion, to continue to enhance its powerful database and to pursue opportunities that emerge in this fast-growing space.

Genomics has developed a unique analysis engine which uses genetics to understand human biology and the likely efficacy and safety of potential novel medicines. The Genomics engine is the largest of its kind in the world, with over 100 billion data points. It links human genetic variation at over 14 million positions in the human genome to changes in 7,000 molecular, cellular, and physiological measurements and disease outcomes. The company uses breakthrough proprietary machine learning and statistical algorithms to predict the impact of therapeutic interventions.

Professor Peter Donnelly FRS, Founder and CEO, Genomics plc, said: “We are delighted to be supported by such a strong cadre of strategic and institutional investors. This fundraising will help us leverage our deep expertise in data science and genetics, our world-leading database of genomic information, and proprietary machine-learning algorithms to help bring greater precision to the discovery of new drugs.”

Notes

(1) – Tanarra invested via Tamorer Pty Ltd

Contact

Ben Atwell and Andrew Ward at FTI Consulting
+44 (0)20 3720 1000
scgenomicsplc@fticonsulting.com